Intrapharm Laboratories is pleased to announce the launch of Inhixa (Enoxaparin Sodium), a biosimilar for VTE prophylaxis and DVT treatment now available for UK patients.
Inhixa (Enoxaparin Sodium) has clinically proven efficacy, with the same range of indications, dosages and pharmaceutical form as the innovator drug Clexane. It comes in pre-filled syringes, with an active safety device (needle guard) to reduce the incidence of needle stick injury, supporting patient and healthcare professional safety.
Kevin James, Chairman and CEO of Intrapharm Laboratories, said: “We are extremely excited by this product launch and are committed to providing a continuity of supply in the marketplace that has seen recent volatility and product shortages.”
Inhixa (Enoxaparin Sodium) is indicated for the treatment of prophylaxis of venous thromboembolism; deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism; unstable angina and non-Q-wave myocardial infarction, in combination with acetylsalicylic acid (ASA); acute ST-segment elevation myocardial infarction (STEMI); blood clot prevention in the extracorporeal circulation during haemodialysis. Trade contact: [email protected]

LEAVE A REPLY